

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 60

May 21, 2018

ISSUE No.

1547

### IN THIS ISSUE

In Brief: Restrictions on *Essure* ..... p 90

## Important Copyright Message

### FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 60 (Issue 1547)

May 21, 2018

Take CME Exams

### IN BRIEF

#### Restrictions on *Essure*

*Essure* (Bayer) is the only nonsurgical, permanent contraceptive available in the US. The coil-like devices are placed hysteroscopically in both fallopian tubes and, after several months, scar tissue causes tubal occlusion.<sup>1</sup> In 2016, the FDA required Bayer to revise the device's labeling to include a patient decision checklist and a boxed warning about the risks of uterine and fallopian tube perforation, migration of the device to the abdominal or pelvic cavity, persistent pain, and hypersensitivity reactions. Some women were apparently not being informed of these risks before implantation of the device, which can only be removed surgically. As a result, the FDA is now restricting the sale and distribution of *Essure* to healthcare providers who agree to review the "Patient-Doctor Discussion Checklist – Acceptance of Risk and Informed Decision Acknowledgement" with their patients before implantation. The checklist includes information about the device, its safety, and its effectiveness. Patients and physicians must sign the checklist before the device is implanted.

From its approval in 2002 through 2017, the FDA received 26,773 medical device reports related to *Essure*. The most common adverse effects reported with its use were abdominal pain, heavier menses/menstrual irregularities, headache, fatigue, and weight fluctuations. Nickel allergy, migration of the device, dislodged or dislocated device, and device breakage have also been reported. During this time period, there were 1863 pregnancies (365 live births, 875 miscarriages, 623 unspecified) and 13 deaths (8 adults, 4 infants after live birth, 1 unspecified).<sup>2</sup>

Bayer states that more than 750,000 women have received *Essure* worldwide, but the device was taken off the market in the United Kingdom, the Netherlands, Finland, and Canada, and Bayer stopped sales of *Essure* outside the US altogether in September 2017.

Some women with contraindications or intolerance to hormonal contraceptives are also poor candidates for laparoscopic tubal ligation, leaving them few options for highly effective contraception. For these women, in the US, *Essure* remains an option. ■

1. Choice of contraceptives. *Med Lett Drugs Ther* 2015; 57:127.
2. FDA activities: *Essure*. Available at: [www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/EssurePermanentBirthControl/ucm452254.htm](http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/EssurePermanentBirthControl/ucm452254.htm). Accessed May 10, 2018.

Follow us on Twitter  Like us on Facebook 

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; **EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D.; **CONSULTING EDITORS:** Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; F. Estelle R. Simons, M.D., F.R.C.P.C., F.R.S.C., University of Manitoba; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **ASSISTANT MANAGING EDITOR:** Liz Donohue

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **SITE LICENSE SALES:** Elaine Reaney-Tomaselli; **EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **VICE PRESIDENT AND PUBLISHER:** Yosef Wissner-Levy

Founded in 1959 by  
Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

**Address:**  
The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537  
www.medicalletter.org

**Customer Service:**  
Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: custserv@medicalletter.org

**Permissions:**  
To reproduce any portion of this issue,  
please e-mail your request to:  
permissions@medicalletter.org

**Subscriptions (US):**  
1 year - \$159; 2 years - \$298;  
3 years - \$398. \$65 per year  
for students, interns, residents, and  
fellows in the US and Canada.  
Reprints - \$25/article, \$35/issue

**Site License Inquiries:**  
E-mail: SubQuote@medicalletter.org  
Call: 800-211-2769  
Special rates available for bulk  
subscriptions.

Get Connected:  

Copyright 2018. ISSN 1543-2859

The  
Medical  
Letter